Cite
HARVARD Citation
Webster, J. et al. (2021). A phase II study of azacitidine in combination with granulocyte-macrophage colony-stimulating factor as maintenance treatment, after allogeneic blood or marrow transplantation in patients with poor-risk acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Leukemia & lymphoma. 62 (13), pp. 3181-3191. [Online].